Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cofetuzumab pelidotin |
Synonyms | |
Therapy Description |
Cofetuzumab pelidotin (PF-06647020) is an antibody-drug conjugate comprising a monoclonal antibody against PTK7 linked to Aur0101, which delivers the cytotoxic agent to PTK7-expressing tumor cells, leading to cell death (PMID: 28077676). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cofetuzumab pelidotin | h6M24-vc0101|PTK7-targeted antibody-drug conjugate|ABBV-647|PF-06647020 | Cofetuzumab pelidotin (PF-06647020) is an antibody-drug conjugate comprising a monoclonal antibody against PTK7 linked to Aur0101, which delivers the cytotoxic agent to PTK7-expressing tumor cells, leading to cell death (PMID: 28077676). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02222922 | Phase I | Avelumab + Cofetuzumab pelidotin Fluconazole Cofetuzumab pelidotin | A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors | Completed | USA | ESP | 0 |
NCT04189614 | Phase I | Cofetuzumab pelidotin | An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer | Active, not recruiting | USA | ISR | ESP | 3 |